Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10203MR)

This product GTTS-WQ10203MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000885.6; NM_000889.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695
UniProt ID P13612; P26010
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10203MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15273MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ3093MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ10958MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ12271MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MRA
GTTS-WQ14594MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ15872MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ1558MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ4989MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA C4G1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW